Pregnancy in systemic lupus erythematosus.

Area of Science:

• Rheumatology
• Obstetrics
• Immunology

Background:

• Systemic lupus erythematosus (SLE) presents unique challenges during pregnancy.
• Monitoring lupus activity and predicting pregnancy outcomes in SLE patients requires careful consideration.

Purpose of the Study:

• To evaluate the impact of pregnancy on SLE activity.
• To assess the role of anti-phospholipid antibodies in fetal loss among SLE patients.
• To determine the efficacy of prednisone therapy and identify risk factors for adverse fetal outcomes.

Main Methods:

• Analysis of data from over 150 pregnancies in women with SLE.
• Evaluation of conventional lupus activity markers during pregnancy.
• Assessment of anti-phospholipid antibody prevalence and its association with fetal outcomes.
• Review of prednisone therapy effects and neonatal lupus incidence.

Main Results:

• Conventional lupus activity markers (complement, platelet count, urinary protein) are unreliable during pregnancy.
• Pregnancy does not precipitate lupus exacerbations.
• Anti-phospholipid antibodies are common and associated with fetal loss, but not the sole determinant.
• Specific antibody characteristics do not predict poor fetal outcomes.
• Prednisone therapy did not improve fetal prognosis.
• Neonatal lupus (rash, thrombocytopenia) is common, but congenital heart block is rare.

Conclusions:

• Pregnancy does not worsen systemic lupus erythematosus (SLE).
• Anti-phospholipid antibodies are significant but not the sole predictor of fetal loss in SLE pregnancies.
• Current monitoring and treatment strategies may require adjustment for pregnant SLE patients.